Table 1 Characteristics of included studies
From: Prevalence of metabolic syndrome in ankylosing spondylitis: a multi national meta-analysis study
No. | Authors | Year | Country | Study Papulation | MetS Prevalence | Disease Duration (Year) | As Criteria | MetS Criteria | AS Activity Scoring | Sample size Lab Data | Quality Assessment | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sample size | Mean age | BMI | Male | Female | No. patients | Prevalence (%) | BASDAI | ASDAS-CRP | ESR (mm/h) | CRP (mg/L) | TG (mg/dl) | TC (mg/dl) | Glucose (mg/dl) | ||||||||
1 | Akaltun et al. [21] | 2021 | Turkey | 67 | 36.79 | 28.15 | 55 | 12 | 23 | 34.3% | 7.1 | Modified New York criteria | NCEP-ATP III | 4.33 | NA | 15.55 | 7.34 | 149.83 | NA | 96.64 | 8 |
2 | Amaricai et al. [30] | 2018 | Romania | 115 | NA | NA | NA | NA | 16 | 13.9% | NA | NA | NCEP-ATP III | NA | NA | NA | NA | NA | NA | NA | 4 |
3 | Batmaz et al. [27]t | 2011 | Turkey | 50 | 34.14 | NA | 40 | 10 | 6 | 12.0% | NA | Modified New York criteria | NCEP-ATP III | NA | NA | 16.08 | 2.1 | 147.17 | 175.89 | 93.32 | 9 |
4 | Chimenti et al. [31] | 2020 | Italy | 39 | 44.8 | 24.4 | 20 | 19 | 9 | 23.1% | 12.5 | Modified New York criteria | IRS | 5.5 | 1.2 | 26.7 | 1.2 | NA | NA | NA | 10 |
5 | El Hassani Sbai et al. [32] | 2019 | Morocco | 110 | 35.8 | 24.17 | 75 | 35 | 9 | 8.2% | NA | Modified New York criteria | JC, IDF, NCEP, WHO, EGIR | 4.41 | NA | 20.2 | 11.17 | NA | NA | NA | 8 |
6 | Gado et al. [33] | 2022 | Egypt | 40 | 42.78 | 24.65 | 40 | 0 | 15 | 37.5% | 9.55 | ASAS | IDF | NA | 0.58 | 46.33 | 7.05 | 145.58 | 223 | 92.78 | 8 |
7 | Halvorsen et al. [34] | 2013 | Norway | 126 | 47.9 | 25.4 | 78 | 48 | 26 | 20.6% | NA | Modified New York criteria | IDF | NA | 1 | NA | 3 | 106.3 | NA | 90 | 8 |
8 | Kesikburun et al. [28] | 2018 | Turkey | 57 | 42.33 | 28.13 | 25 | 32 | 14 | 24.6% | 6.38 | Modified New York criteria | IDF | 2.4 | NA | 20 | 10.2 | 128.13 | NA | 87.61 | 8 |
9 | Lai et al. [35] | 2022 | Taiwan | 5,905 | 37.72 | NA | 3,255 | 2,650 | 194 | 3.3% | NA | ICD-9-CM | NA | NA | NA | NA | NA | NA | NA | NA | 10 |
10 | Lin et al. [36] | 2022 | Taiwan | 2,650 | 37.72 | NA | 1,480 | 1,170 | 90 | 3.4% | NA | ICD-9-CM | NA | NA | NA | NA | NA | NA | NA | NA | 10 |
11 | Liu et al. [8] | 2019 | China | 117 | 35 | 22.9 | 97 | 20 | 23 | 19.7% | NA | Modified New York criteria | CDS | NA | NA | NA | NA | 106.3 | 162.4 | 90 | 8 |
12 | Maia et al. [7] | 2017 | Brazil | 63 | 41.6 | 27.6 | 53 | 10 | 17 | 27.0% | NA | Modified New York criteria | NCEP-ATP III | NA | NA | NA | NA | 131.4 | 190.9 | 104.4 | 6 |
13 | Malesci et al. [19] | 2007 | Italy | 24 | 50.5 | 29.2 | 21 | 3 | 11 | 45.8% | NA | Modified New York criteria | NCEP-ATP III | 21.3 | NA | NA | NA | 141 | 205 | NA | 9 |
14 | Mok et al. [37] | 2011 | Hong Kong | 122 | 39 | 23.3 | 94 | 28 | 13 | 10.7% | 6 | Modified New York criteria | IDF | NA | NA | NA | NA | 88.6 | 196.1 | 89.6 | 8 |
15 | Papadakis et al. [38] | 2009 | Greece | 63 | 40 | NA | 63 | 0 | 22 | 34.9% | NA | Modified New York criteria | NCEP ATP III | NA | NA | NA | NA | 114 | 197 | 91 | 9 |
16 | Petcharat et al. [39] | 2021 | Thailand | 153 | 41.7 | 23.4 | 94 | 59 | 29 | 19.0% | 10 | Modified New York criteria | Harmonized definition | NA | 1.1 | NA | NA | NA | NA | NA | 8 |
17 | Sari et al. [29] | 2010 | Turkey | 45 | 37.4 | 25 | 35 | 10 | 0 | 0.0% | NA | Modified New York criteria | NA | NA | NA | 11 | NA | 95.7 | 173.7 | 91 | 9 |